X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP Explained: Three forms of IP protections for medicines

By Tom Wilbur  |    August 27, 2019
Intellectual property (IP) protections for the biopharmaceutical sector provide incentives that help to promote the discovery and development of life-saving medicines for patients and foster a...   Read More

Three reasons the Senate Finance package is the wrong approach for patients

By Tom Wilbur  |    August 26, 2019
For more than a decade, Medicare Part D has successfully provided seniors and people with disabilities comprehensive prescription drug coverage, while its unique market-based structure has kept...   Read More

Fact Check: How hospitals continue to drive health care spending

By Nicole Longo  |    August 21, 2019
There is a lot of talk about health care costs in the United States that is mostly centered on prescription medicine spending, overlooking the largest share of U.S. health care spending – hospital...   Read More

340B Spotlight: How for-profit middlemen are taking advantage of a program meant to support nonprofit entities and patients

By Nicole Longo  |    August 20, 2019
Congress created the 340B program to help safety-net providers, like federally-funded safety net clinics, access discounts on prescription medicines for vulnerable or uninsured patients....   Read More

New analysis: Government intervention in Part B threatens patient access to medicines

By Nicole Longo  |    August 19, 2019
A new analysis from Avalere looked at how access to medicines in Part B may be impacted if the government only covered a certain list of medicines, an approach known as applying a national...   Read More

Three things to know about the Part D GAO report

By Nicole Longo  |    August 16, 2019
The Government Accountability Office (GAO) recently released a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a...   Read More

Four Things You Should Know About AARP

By Tom Wilbur  |    August 14, 2019
As lawmakers in Washington consider policies to make changes to Medicare prescription drug coverage, one solution that would provide immediate relief is sharing the savings biopharmaceutical...   Read More

What they’re saying: Safety is top concern for recent drug importation proposal

By Nicole Longo  |    August 8, 2019
Last week, the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) released their “Safe Importation Action Plan,” which would allow importation of...   Read More

IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle

By Tom Wilbur  |    August 6, 2019
Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell...   Read More

ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals

By Tiffany Haverly  |    August 1, 2019
This week, the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced their “Safe Importation Action Plan.” While patients are rightfully concerned about...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates